GeoVax Labs postpones proposed public offering

Jul 1 2010

GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), a biotechnology company dedicated to developing vaccines that prevent and fight human immunodeficiency virus (HIV), today announced that it has decided to postpone its proposed public offering of units, each consisting of a share of common stock and a warrant to purchase another share.

"Due to unfavorable market conditions, our board has determined it is in the best interest of our stockholders to postpone the offering,'' said Robert McNally, PhD, President and CEO.  "We intend to consult with our advisors and re-evaluate the size and structure of our proposed offering."

SOURCE GeoVax Labs, Inc.

Posted in:

Tags: , , , , , , , ,

Comments (0)

Suggested Reading

Pittcon to make historic first appearance in Boston’s world-leading scientific hub
Monmouth Scientific Modular Cleanroom expansion enhances production for Womed
UQ and Vaxxas win global prize to accelerate patch-based mRNA vaccine for COVID-19
Pheno Therapeutics receives clinical trial authorization for novel multiple sclerosis therapeutic
A new era of targeted therapy with antibody–drug conjugates
Enhanced biosensing technology detects molecules at lower concentrations
Insilico Medicine nominates ISM1745 as preclinical candidate for MTAP-deleted cancers
Spear Bio secures FDA breakthrough device designation for its novel pTau 217 blood test, advancing scalable solutions for early Alzheimer's disease diagnosis

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Breakthrough in antigen recognition: TRACeR-I enhances immune targeting